FBLG
FibroBiologics, Inc. Common Stock NASDAQ$1.38
Mkt Cap $2.9M
52w Low $1.03
1.6% of range
52w High $22.60
50d MA $3.90
200d MA $7.36
P/E (TTM)
-0.2x
EV/EBITDA
-0.4x
P/B
0.5x
Debt/Equity
0.4x
ROE
-302.9%
P/FCF
-0.6x
RSI (14)
—
ATR (14)
—
Beta
1.10
50d MA
$3.90
200d MA
$7.36
Avg Volume
347.8K
About
FibroBiologics, Inc., a clinical-stage cell therapy company, develops and commercializes fibroblast-based therapies in the United States. It is developing CybroCell, for the treatment of degenerative disc disease; CYMS101 to treat multiple sclerosis; and CYWC628 for wound healing. The company is also on the early-stage research of CYTER915, which is designed to regenerate or reinvigorate productio…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 30, 2026 | AMC | -1.33 | -1.33 | +0.3% | 1.32 | -2.3% | +10.6% | +4.5% | +7.6% | — | — | — |
| Feb 24, 2026 | AMC | -1.44 | -0.98 | +31.9% | 5.35 | -3.4% | -1.5% | +5.8% | +22.8% | +56.8% | +45.4% | — |
| Oct 31, 2025 | AMC | -0.10 | -0.13 | -30.0% | 7.87 | -2.9% | +0.3% | -16.9% | -5.8% | -14.9% | -10.4% | — |
| Jul 31, 2025 | AMC | -0.11 | -0.12 | -9.1% | 12.74 | +0.0% | +1.8% | -4.5% | -12.8% | -15.8% | -16.2% | — |
| Mar 31, 2025 | AMC | -0.10 | -0.09 | +10.0% | 18.00 | +11.1% | -4.4% | +4.1% | -2.8% | -2.7% | -3.3% | — |
| Mar 27, 2025 | AMC | -0.10 | -0.09 | +5.7% | 20.40 | -1.0% | -6.9% | -11.8% | -15.7% | -8.2% | -14.2% | — |
| Nov 12, 2024 | AMC | -0.08 | -0.08 | +0.0% | 63.40 | +0.0% | -2.8% | -11.4% | -18.6% | -20.8% | -24.9% | — |
| Aug 7, 2024 | AMC | -0.09 | -0.09 | +0.0% | 74.60 | -0.8% | -39.4% | -47.2% | -50.9% | -49.6% | -53.9% | — |
| May 14, 2024 | AMC | — | -0.27 | — | 226.00 | +2.2% | +1.7% | +4.4% | +0.4% | -2.7% | -2.7% | — |
| Dec 31, 2023 | AMC | — | -0.34 | — | — | — | — | — | — | — | — | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.54 | $1.49 | -3.2% | -1.3% | -0.6% | -0.6% | -1.3% | +1.3% |
| Mar 26 | D. Boral Capital | Downgrade | Buy → Hold | — | $5.27 | $4.29 | -18.6% | -16.5% | -25.4% | -56.7% | -75.0% | -74.8% |
| Mar 12 | D. Boral Capital | Maintains | Buy → Buy | — | $6.80 | $6.80 | +0.0% | +0.0% | -8.1% | -17.1% | -18.8% | -23.4% |
| Feb 26 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.27 | $5.62 | +6.6% | +7.4% | +24.7% | +59.2% | +47.6% | +42.5% |
| Feb 25 | D. Boral Capital | Maintains | Buy → Buy | — | $5.35 | $5.17 | -3.4% | -1.5% | +5.8% | +22.8% | +56.8% | +45.4% |
| Jan 6 | D. Boral Capital | Maintains | Buy → Buy | — | $4.87 | $4.90 | +0.6% | +6.8% | +41.3% | +35.5% | +38.8% | +58.3% |
| Jan 2 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.50 | $4.78 | +6.2% | +6.7% | +8.2% | +15.6% | +52.9% | +46.7% |
| Nov 20 | D. Boral Capital | Maintains | Buy → Buy | — | $6.89 | $6.97 | +1.2% | -5.8% | -1.3% | -24.5% | -22.2% | -21.0% |
| Nov 5 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.54 | $6.84 | +4.6% | +13.3% | +2.4% | +7.8% | +9.2% | +3.2% |
| Nov 3 | D. Boral Capital | Maintains | Buy → Buy | — | $7.87 | $7.64 | -2.9% | +0.3% | -16.9% | -5.8% | -14.9% | -10.4% |
Recent Filings
8-K · 5.02
!!! Very High
FibroBiologics, Inc. -- 8-K 5.02: Executive Change
FibroBiologics granted equity awards to its CFO, Chief Scientific Officer, and another executive, signaling management retention efforts as the biotech company pursues its clinical development programs.
May 5
8-K · 1.01
!! High
FibroBiologics, Inc. -- 8-K 1.01: Material Agreement
FibroBiologics has authorized an at-the-market offering agreement, allowing the company to sell shares opportunistically for capital raising without upfront dilution commitments.
May 1
8-K · 8.01
!! High
FibroBiologics, Inc. -- 8-K 8.01: Material Event / Announcement
FibroBiologics resolved its Nasdaq listing deficiency by meeting the minimum bid price requirement, securing continued listing on Nasdaq Capital Market and eliminating delisting risk.
Apr 20
8-K · 5.03
! Medium
FibroBiologics, Inc. -- 8-K 5.03: Amendment to Articles / Bylaws
FibroBiologics changed its fiscal year end, which may affect the timing and comparability of its future financial reporting for investors tracking the company's performance.
Apr 17
8-K · 1.01
!! High
Unknown — 8-K 1.01: Material Agreement
United Fire Casualty's material agreement with FBLG/UFCS could signal a major partnership or insurance underwriting deal that may significantly expand revenue streams and market reach for both companies.
Apr 9
8-K · 1.01
!! High
Unknown — 8-K 1.01: Material Agreement
United Fire Casualty's material agreement with UFCS likely involves a significant insurance underwriting or distribution partnership that could expand UFCS's revenue streams and market reach substantially.
Apr 9
8-K · 5.03
! Medium
Unknown — 8-K 5.03: Amendment to Articles / Bylaws
FBLG executed a reverse stock split to consolidate shares and adjust equity incentives accordingly, likely signaling financial distress or exchange compliance needs that could dilute existing shareholders despite the mechanical share reduction.
Apr 3
8-K · 1.01
!! High
Unknown — 8-K 1.01: Material Agreement
FBLG shareholders face potential dilution as insiders' lock-up expiration approaches, likely triggering substantial share sales that could pressure the stock price when the restriction ends.
Apr 2
8-K · 5.02
!!! Very High
FibroBiologics, Inc. -- 8-K 5.02: Executive Change
FibroBiologics dismissed its Chief Financial Officer Davis, signaling potential leadership restructuring that investors should monitor for impacts on financial reporting and strategic direction.
Mar 6
8-K
FibroBiologics, Inc. -- 8-K Filing
FibroBiologics filed an 8-K current report, indicating a material event occurred at the Delaware-incorporated biopharmaceutical company that requires investor disclosure under SEC regulations.
Feb 23
Data updated apr 25, 2026 8:30am
· Source: massive.com